<DOC>
	<DOCNO>NCT00936650</DOCNO>
	<brief_summary>This randomize , placebo-controlled study patient primary HPT design evaluate efficacy , safety , pharmacokinetics , health-related quality life ( HRQOL ) AMG 073 administer 2 time day ( BID ) . The study consist 3 phase : 12-week dose-titration phase , 12-week maintenance phase , 28-week follow-up phase .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Twice-Daily Dose Regimens Oral Calcimimetic Agent AMG 073 ( Cinacalcet ) Primary Hyperparathyroidism ( PHPT )</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<mesh_term>Calcimimetic Agents</mesh_term>
	<criteria>Men woman ≥ 18 year age screen Using , opinion principal investigator , effective contraceptive measure Plasma iPTH concentration &gt; 45 pg/mL least 2 occasion least 7 day apart 12 month precede day 0 ( least 1 determination make screen central lab ) serum calcium concentration &gt; 10.3 mg/dL ≤ 12.5 mg/dL least 2 occasion least 7 day apart Acceptable renal function , estimate creatinine clearance &gt; 50 mL/min determine Cockroft Gault equation Acceptable hepatic function , define serum aspartate aminotransferase , alanine aminotansferase , total bilirubin ≤ 2 time upper limit normal accord range provide central laboratory Laboratory test result within central laboratory 's normal range hematology , urinalysis , clinical chemistry parameter mention specifically inclusion exclusion criterion Chest xray within previous 12 month without evidence active infectious , inflammatory , malignant process Subject legally acceptable representative give inform consent participation study Unstable medical condition , define hospitalize within 30 day day 0 Pregnant nursing Body habitus preclude accurate DXA measurement Therapy within 21 day day 0 systemic glucocorticoid , lithium , tricyclic antidepressant exception amitriptyline nortryptiline , thioridazine , haloperidol , flecainide drug narrow therapeutic index primarily metabolize hepatic cytochrome P450 ( CYP ) 2D6 , drug affect renal tubular calcium handling ( eg , thiazide loop diuretic ) , calcitonin Received , within 90 day day 0 , therapy bisphosphonates , fluoride , change thyroid replacement therapy Dose change selective estrogen receptor modulators ( SERMs ) , significant change dose estrogen within 90 day day 0 . If subject discontinue estrogen SERM therapy , must treatment least 90 day day 0 Alcohol abuse , use illicit drug , within 12 month day 0 Myocardial infarction ( MI ) within 6 month day 0 Ventricular rhythm disturbance require current treatment Seizures within 12 month day 0 History ( within 5 year ) malignancy type , nonmelanomatous skin cancer situ cervical cancer Within past 5 year , evidence treatment and/or active sarcoidosis , tuberculosis , diseases know cause hypercalcemia History familial hypocalciuric hypercalcemia ( FHH ) Uncontrolled diabetes , define hemoglobin A1c ( HbA1c ) ≥ 8.0 Gastrointestinal disorder might associate impaired absorption orally dministered medication Inability swallow tablet Known sensitivity product administer study Psychiatric disorder would interfere understanding give informed consent compliance protocol requirement Other condition might reduce chance obtain data ( eg , know poor compliance ) require protocol might compromise ability give truly informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hyperparathyroidism , Primary</keyword>
	<keyword>cinacalcet</keyword>
</DOC>